GEN Exclusives

More »

GEN News Highlights

More »
Jun 15, 2012

Life Technologies Gains Rights to iPS Academia Japan’s Patents

  • Life Technologies entered a nonexclusive agreement with iPS Academia Japan for its induced pluripotent stem cell (iPSC) patent portfolio. The worldwide license will enable Life Technologies to expand its range of products and services for the iPSC research community.

    By leveraging its expertise in stem cell tool manufacturing and its global distribution network, Life Technologies believes that it is now positioned to develop and commercialize products designed to create iPSCs and differentiate them into any cell type for use in drug discovery and preclinical research. In addition to directly selling iPSCs, the deal enables the company to provide iPSC creation, differentiation, and screening services for scientists around the world.

    “Because iPS cells are gaining greater attention for uses in drug discovery and disease research as well as other areas of biotechnology, distribution of iPS cell products or provision of services is important for gaining momentum in iPS cell research,” says Shosaku Murayama, president and CEO of iPS Academia Japan. “We believe that Life Technologies' business will contribute to boost research and development for practical application of iPS cell technology.”

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »